Concord Healthcare Group Co., Ltd. Class H (HK:2453)
:2453
Want to see HK:2453 full AI Analyst Report?
2453 Stock Chart & Stats
HK$1.83
-HK$0.24(-2.76%)
At close: 4:00 PM EST
HK$1.83
-HK$0.24(-2.76%)
Day’s Range― - ―
52-Week RangeHK$0.80 - HK$7.91
Previous CloseN/A
Volume2.50M
Average Volume (3M)590.21K
Market Cap
HK$689.62M
Enterprise ValueHK$3.41B
Total Cash (Recent Filing)HK$319.01M
Total Debt (Recent Filing)HK$3.09B
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding313,874,630
10 Day Avg. Volume440,520
30 Day Avg. Volume590,206
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Margin RecoveryRevenue recovery and a return to roughly 7% gross margin in 2025 indicate the core care-services offering can regain demand and/or pricing. If sustained, this improves operating leverage, helps absorb fixed costs, and creates a credible pathway toward narrowing losses and eventual profitability.
Improved Leverage And Equity BaseA reduction in debt-to-equity and an increased equity base in 2025 reduce immediate solvency pressure versus the prior year. This incremental balance-sheet repair enhances runway for executing turnaround plans, lowers near-term refinancing urgency, and supports selective investment if operational cash conversion improves.
Demonstrated Cash-generation PotentialHaving produced positive operating cash flow in 2023 shows the business can convert revenue to cash when operations normalize. That historical capability implies latent cash-conversion potential which management could recapture through sustained margin improvements, utilization gains, and tighter working-capital management.
Bears Say
Deep Operating And Net LossesLarge operating and net losses in 2025 indicate the company remains structurally unprofitable. Persistent deep deficits erode shareholder equity, limit the ability to internally fund growth or service debt, and mean the firm will rely on decisive margin improvement or external capital to reach sustainable operations.
Negative Cash Flow TrendConsecutive years of negative operating and free cash flow despite revenue gains signal weak cash conversion and current cash burn. Continued negative cash flow increases reliance on external financing, raises dilution or refinancing risk, and constrains the ability to invest in quality improvements or repay debt over the next several quarters.
Elevated Leverage And Poor ReturnsElevated leverage combined with a negative ROE undermines financial flexibility; debt servicing consumes resources that otherwise could support operations or investment. Until profitability and cash flow turn positive, the company remains exposed to creditor pressure and limited in executing strategic initiatives without raising new capital.
Concord Healthcare Group Co., Ltd. Class H News
2453 FAQ
What was Concord Healthcare Group Co., Ltd. Class H’s price range in the past 12 months?
Concord Healthcare Group Co., Ltd. Class H lowest stock price was HK$0.80 and its highest was HK$7.91 in the past 12 months.
What is Concord Healthcare Group Co., Ltd. Class H’s market cap?
Concord Healthcare Group Co., Ltd. Class H’s market cap is HK$689.62M.
When is Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date?
Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 73 days.
How were Concord Healthcare Group Co., Ltd. Class H’s earnings last quarter?
Concord Healthcare Group Co., Ltd. Class H released its earnings results on Mar 26, 2026. The company reported -HK$0.112 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.112.
Is Concord Healthcare Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Concord Healthcare Group Co., Ltd. Class H’s price is currently Overvalued.
Does Concord Healthcare Group Co., Ltd. Class H pay dividends?
Concord Healthcare Group Co., Ltd. Class H does not currently pay dividends.
What is Concord Healthcare Group Co., Ltd. Class H’s EPS estimate?
Concord Healthcare Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Healthcare Group Co., Ltd. Class H have?
Concord Healthcare Group Co., Ltd. Class H has 313,874,630 shares outstanding.
What happened to Concord Healthcare Group Co., Ltd. Class H’s price movement after its last earnings report?
Concord Healthcare Group Co., Ltd. Class H reported an EPS of -HK$0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of Concord Healthcare Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2453
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Concord Healthcare Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.59%
12-Months-Change
Fundamentals
Return on Equity
-15.15%
Trailing 12-Months
Asset Growth
2.55%
Trailing 12-Months
Company Description
Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Technical Analysis
C-MER Eye Care Holdings Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―